Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rosuvastatin in Primary Sclerosing Cholangitis
NCT05912387Phase 1Recruiting
- Sponsor
- Stanford University
- Start
- May 2023
- Primary completion
- May 2027
- Modality
- Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rosuvastatin in Primary Sclerosing Cholangitis (PSC), sponsored by Stanford University. Primary endpoints: Change in total bile acid profile at 14 weeks, Change in secondary bile acids to primary bile acids ratio at 14 weeks and 3 more. Started May 2023; status: recruiting.
02
Drugs
rosuvastatin
03
Conditions
Primary Sclerosing Cholangitis (PSC)
Beyond the preview
Go deeper on NCT05912387.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05912387.